Eli Lilly CEO Dave Ricks revealed that since Medicare began covering obesity drugs in July, 700,000 new seniors have started GLP-1 treatments, with 70% of those patients using Lilly medicines [1]. This expansion is facilitated by a temporary program called 'Bridge,' which allows eligible Medicare beneficiaries to access weight loss drugs for a $50 monthly co-pay [1]. Medicare covers approximately 66 million people aged 65 and older or with disabilities [1].
Lilly's obesity injection Zepbound has emerged as the leading beneficiary of the new coverage, with many seniors opting for this treatment. The program also provides access to Lilly's recently launched obesity pill, Foundayo, as well as Novo's competing Wegovy pill and injection [1]. Ricks noted that physicians are primarily focusing on patients with significant body weight and complications, where Zepbound plays a crucial role [1]. For those seeking a more convenient option or needing to lose 25 to 30 pounds, Foundayo is increasingly popular, accounting for one-third of new oral GLP-1 patients despite launching a few months after Novo's pill [1].
Ricks described the rollout as 'very encouraging,' emphasizing that the expansion of the broader GLP-1 market aligns with Lilly's expectations [1]. He also stated that there have been few logistical issues, crediting the Centers for Medicare and Medicaid Services for effectively educating physicians and collaborating with both pharmaceutical companies and the insurance system [1].
These developments highlight Lilly's strong position in the expanding Medicare GLP-1 market, with the company capturing about seven out of ten new patients and maintaining momentum against its chief rival, Novo [1].
CONCLUSION
Eli Lilly has quickly established dominance in the Medicare GLP-1 market following the launch of obesity drug coverage, capturing 70% of new senior patients. The positive rollout and strong uptake of Zepbound and Foundayo signal significant market growth and favorable conditions for Lilly. The company's leadership and effective collaboration with Medicare suggest continued momentum in this sector.